ProShare Advisors
BIO icon

ProShare Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

ProShare Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
730
+1
+0.1% +$288 ﹤0.01% 1572
2025
Q4 		$221K Sell
729
-48
-6% -$15K ﹤0.01% 1654
2025
Q3 		$218K Buy
+777
New +$211K ﹤0.01% 1651
2025
Q1 		– Sell
-901
Closed -$296K – 2106
2024
Q4 		$296K Buy
901
+67
+8% +$22.7K ﹤0.01% 1644
2024
Q3 		$279K Sell
834
-2,125
-72% -$675K ﹤0.01% 1517
2024
Q2 		$808K Buy
2,959
+126
+4% +$36.6K ﹤0.01% 793
2024
Q1 		$980K Sell
2,833
-57
-2% -$18.7K ﹤0.01% 793
2023
Q4 		$933K Sell
2,890
-273
-9% -$85.6K ﹤0.01% 771
2023
Q3 		$1.13M Sell
3,163
-220
-7% -$84.9K ﹤0.01% 709
2023
Q2 		$1.28M Sell
3,383
-19
-0.6% -$7.73K ﹤0.01% 691
2023
Q1 		$1.63M Buy
3,402
+493
+17% +$231K 0.01% 671
2022
Q4 		$1.22M Buy
2,909
+31
+1% +$12.5K ﹤0.01% 697
2022
Q3 		$1.2M Sell
2,878
-404
-12% -$201K ﹤0.01% 705
2022
Q2 		$1.62M Sell
3,282
-4,090
-55% -$2.13M 0.01% 681
2022
Q1 		$4.15M Buy
7,372
+526
+8% +$317K 0.01% 590
2021
Q4 		$5.17M Buy
6,846
+1,222
+22% +$914K 0.01% 558
2021
Q3 		$4.2M Sell
5,624
-658
-10% -$493K 0.01% 543
2021
Q2 		$4.05M Buy
6,282
+687
+12% +$418K 0.01% 539
2021
Q1 		$3.2M Buy
5,595
+209
+4% +$124K 0.01% 561
2020
Q4 		$3.14M Buy
5,386
+216
+4% +$123K 0.01% 528
2020
Q3 		$2.67M Buy
5,170
+2,606
+102% +$1.32M 0.01% 512
2020
Q2 		$1.16M Buy
2,564
+1,379
+116% +$609K 0.01% 668
2020
Q1 		$415K Sell
1,185
-1,167
-50% -$429K ﹤0.01% 778
2019
Q4 		$870K Buy
2,352
+226
+11% +$79.7K ﹤0.01% 842
2019
Q3 		$707K Buy
2,126
+43
+2% +$14K ﹤0.01% 865
2019
Q2 		$651K Sell
2,083
-397
-16% -$119K ﹤0.01% 913
2019
Q1 		$758K Buy
2,480
+547
+28% +$148K ﹤0.01% 876
2018
Q4 		$449K Sell
1,933
-434
-18% -$116K ﹤0.01% 987
2018
Q3 		$741K Buy
2,367
+151
+7% +$46.9K 0.01% 948
2018
Q2 		$639K Sell
2,216
-14
-0.6% -$3.87K ﹤0.01% 1010
2018
Q1 		$558K Sell
2,230
-74
-3% -$18.8K ﹤0.01% 1056
2017
Q4 		$550K Buy
2,304
+527
+30% +$128K ﹤0.01% 1087
2017
Q3 		$395K Sell
1,777
-112
-6% -$25.2K ﹤0.01% 1047
2017
Q2 		$427K Sell
1,889
-301
-14% -$65.6K ﹤0.01% 1013
2017
Q1 		$437K Sell
2,190
-136
-6% -$26.2K ﹤0.01% 1057
2016
Q4 		$424K Buy
2,326
+382
+20% +$65.1K ﹤0.01% 1160
2016
Q3 		$318K Sell
1,944
-512
-21% -$77.7K ﹤0.01% 1127
2016
Q2 		$351K Sell
2,456
-2
-0.1% -$285 ﹤0.01% 1129
2016
Q1 		$336K Sell
2,458
-236
-9% -$31K ﹤0.01% 1152
2015
Q4 		$374K Buy
2,694
+271
+11% +$37.6K ﹤0.01% 1184
2015
Q3 		$325K Sell
2,423
-1,308
-35% -$188K ﹤0.01% 1110
2015
Q2 		$562K Sell
3,731
-118
-3% -$16.9K 0.01% 1049
2015
Q1 		$520K Sell
3,849
-448
-10% -$55.5K 0.01% 1155
2014
Q4 		$518K Sell
4,297
-6,761
-61% -$778K 0.01% 1184
2014
Q3 		$1.25M Buy
11,058
+1,244
+13% +$147K 0.02% 989
2014
Q2 		$1.18M Buy
9,814
+7,176
+272% +$876K 0.02% 1087
2014
Q1 		$338K Sell
2,638
-12,336
-82% -$1.58M ﹤0.01% 2164
2013
Q4 		$1.85M Buy
14,974
+12,696
+557% +$1.55M 0.03% 771
2013
Q3 		$268K Buy
+2,278
New +$269K 0.01% 1979

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ProShare Advisors's BIO Position: Q1 2026 in Review

ProShare Advisors increased its Bio-Rad Laboratories Class A (BIO) stake by 0.14% in Q1 2026, buying an estimated $288 and bringing the position to 730 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #1572.

ProShare Advisors first reported a position in BIO in Q3 2013 and has held it in 49 quarters since. The position peaked at $5.17M in Q4 2021. 392 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • ProShare Advisors held 730 shares of Bio-Rad Laboratories Class A worth $203K as of Q1 2026.
  • ProShare Advisors bought 1 Bio-Rad Laboratories Class A share in Q1 2026, an estimated $288.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1572 holding.
  • ProShare Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2013 and has held it in 49 quarters since.
  • ProShare Advisors's Bio-Rad Laboratories Class A position peaked at $5.17M in Q4 2021.
  • 392 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.